Instructions for Galvus (Vildagliptin) 50 mg 28 pills
English product name
Galvus®
Release form
tab 50 mg: 14, 28, 56, 84, 112 or 168 pcs
Description Galvus:
The tablets are white to light yellow, round, smooth, with beveled edges, with the engraving "NVR" on one side and "FB" on the other.
1 tab.
vildagliptin 50 mg
Auxiliary substances: cellulose microcrystalline - 95.68 mg, lactose anhydrous - 47.82 mg, sodium carboxymethyl starch - 4 mg, magnesium stearate - 2.5 mg.
7 pcs. - blisters (8) - packs×
7 pcs. - blisters (12) - packs×
14 pcs. - blisters (4) - packs×
14 pcs. - blisters (8) - packs×
primary dissection control is allowed on the cardboard pack.
ATC codes
A10BH02 Vildagliptin
Use in children
The efficacy and safety of vildagliptin in children and adolescents under 18 years of age are not established.
- Nosology Galvus (ICD codes)
- E11
- Type 2 diabetes
Pharmacological effect:
Hypoglycemic agent. Vildagliptin is a class of pancreatic insular stimulants that selectively inhibits the enzyme dipeptidyl peptidase-4 (DPP-4). Rapid and complete inhibition of DPP-4 activity (>90%) results in increased basal and induced food secretion of type 1 gluconic peptide (GPP-1) and glucose-dependent insulin-tropic polypeptide (IGP) from the intestines to the systemic bloodstream throughout the day.
Testimony:
- Type 2 diabetes:
- as a monotherapy combined with diet and exercise;
- in a two-component combination therapy with metformin,
- sulfonyl urea derivatives,
- thiazolidinedione, or insulin in case of failure of dieting,
- exercise, and monotherapy with these drugs.
Method of use, course and dosage:
The dosing mode is set individually according to the effectiveness, tolerability and treatment regimen.
A single dose is fifty mg, a daily dose is 100 mg (fifty mg twice a day).
